SDI 157

Drug Profile

SDI 157

Latest Information Update: 09 May 2003

Price : $50

At a glance

  • Originator Aventis
  • Class Antihyperglycaemics
  • Mechanism of Action Enzyme inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Diabetic complications

Most Recent Events

  • 09 May 2003 Discontinued for Diabetic complications in Germany (unspecified route)
  • 30 Jan 1997 No-Development-Reported for Diabetic complications in Germany (Unknown route)
  • 20 Oct 1994 Investigation in Diabetic complications in Germany (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top